nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—ABCB1—kidney cancer	0.139	1	CbGaD
Cyclophosphamide—CYP3A7—Temsirolimus—kidney cancer	0.0425	0.0738	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0425	0.0738	CbGbCtD
Cyclophosphamide—CYP3A5—Temsirolimus—kidney cancer	0.0319	0.0553	CbGbCtD
Cyclophosphamide—ABCB1—Temsirolimus—kidney cancer	0.0207	0.036	CbGbCtD
Cyclophosphamide—CYP2D6—Temsirolimus—kidney cancer	0.0195	0.0339	CbGbCtD
Cyclophosphamide—CYP3A4—Everolimus—kidney cancer	0.0184	0.0319	CbGbCtD
Cyclophosphamide—CYP2C8—Pazopanib—kidney cancer	0.0161	0.0279	CbGbCtD
Cyclophosphamide—CYP3A7—Paclitaxel—kidney cancer	0.0146	0.0253	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0146	0.0253	CbGbCtD
Cyclophosphamide—CYP3A7—Sorafenib—kidney cancer	0.013	0.0225	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.013	0.0225	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0126	0.0218	CbGbCtD
Cyclophosphamide—CYP3A7—Vincristine—kidney cancer	0.0126	0.0218	CbGbCtD
Cyclophosphamide—CYP3A4—Temsirolimus—kidney cancer	0.0124	0.0216	CbGbCtD
Cyclophosphamide—CYP2B6—Sorafenib—kidney cancer	0.0123	0.0214	CbGbCtD
Cyclophosphamide—CYP3A5—Erlotinib—kidney cancer	0.0119	0.0207	CbGbCtD
Cyclophosphamide—CYP2C9—Capecitabine—kidney cancer	0.0117	0.0203	CbGbCtD
Cyclophosphamide—CYP2C8—Erlotinib—kidney cancer	0.0115	0.0199	CbGbCtD
Cyclophosphamide—CYP3A5—Paclitaxel—kidney cancer	0.0109	0.019	CbGbCtD
Cyclophosphamide—ABCB1—Pazopanib—kidney cancer	0.0109	0.0189	CbGbCtD
Cyclophosphamide—CYP2C8—Paclitaxel—kidney cancer	0.0105	0.0183	CbGbCtD
Cyclophosphamide—CYP3A7—Sunitinib—kidney cancer	0.0105	0.0182	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.0105	0.0182	CbGbCtD
Cyclophosphamide—CYP2D6—Pazopanib—kidney cancer	0.0103	0.0178	CbGbCtD
Cyclophosphamide—ABCB1—Dactinomycin—kidney cancer	0.00997	0.0173	CbGbCtD
Cyclophosphamide—CYP3A5—Sorafenib—kidney cancer	0.00972	0.0169	CbGbCtD
Cyclophosphamide—CYP3A5—Vincristine—kidney cancer	0.00943	0.0164	CbGbCtD
Cyclophosphamide—CYP2C8—Sorafenib—kidney cancer	0.00934	0.0162	CbGbCtD
Cyclophosphamide—ABCB1—Gemcitabine—kidney cancer	0.00788	0.0137	CbGbCtD
Cyclophosphamide—CYP3A5—Sunitinib—kidney cancer	0.00787	0.0137	CbGbCtD
Cyclophosphamide—CYP2C19—Sorafenib—kidney cancer	0.00784	0.0136	CbGbCtD
Cyclophosphamide—ABCB1—Erlotinib—kidney cancer	0.00778	0.0135	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—kidney cancer	0.00748	0.013	CbGbCtD
Cyclophosphamide—CYP2C9—Paclitaxel—kidney cancer	0.00734	0.0127	CbGbCtD
Cyclophosphamide—CYP2D6—Erlotinib—kidney cancer	0.00733	0.0127	CbGbCtD
Cyclophosphamide—ABCB1—Paclitaxel—kidney cancer	0.00712	0.0124	CbGbCtD
Cyclophosphamide—CYP3A4—Pazopanib—kidney cancer	0.00653	0.0113	CbGbCtD
Cyclophosphamide—CYP2C9—Sorafenib—kidney cancer	0.00652	0.0113	CbGbCtD
Cyclophosphamide—ABCB1—Sorafenib—kidney cancer	0.00632	0.011	CbGbCtD
Cyclophosphamide—ABCB1—Vinblastine—kidney cancer	0.00624	0.0108	CbGbCtD
Cyclophosphamide—ABCB1—Vincristine—kidney cancer	0.00614	0.0107	CbGbCtD
Cyclophosphamide—CYP2D6—Sorafenib—kidney cancer	0.00596	0.0103	CbGbCtD
Cyclophosphamide—CYP2D6—Vinblastine—kidney cancer	0.00588	0.0102	CbGbCtD
Cyclophosphamide—ABCB1—Sunitinib—kidney cancer	0.00512	0.00889	CbGbCtD
Cyclophosphamide—CYP3A4—Erlotinib—kidney cancer	0.00466	0.00809	CbGbCtD
Cyclophosphamide—CYP3A4—Paclitaxel—kidney cancer	0.00427	0.0074	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—kidney cancer	0.00384	0.00666	CbGbCtD
Cyclophosphamide—CYP3A4—Sorafenib—kidney cancer	0.00379	0.00658	CbGbCtD
Cyclophosphamide—CYP3A4—Vinblastine—kidney cancer	0.00374	0.00649	CbGbCtD
Cyclophosphamide—CYP3A4—Vincristine—kidney cancer	0.00368	0.00638	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—kidney cancer	0.00361	0.00627	CbGbCtD
Cyclophosphamide—CYP3A4—Sunitinib—kidney cancer	0.00307	0.00533	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—kidney cancer	0.0023	0.00399	CbGbCtD
Cyclophosphamide—Ifosfamide—PTGS1—kidney cancer	0.00169	1	CrCbGaD
Cyclophosphamide—CYP2C19—urine—kidney cancer	0.00137	0.145	CbGeAlD
Cyclophosphamide—CYP2C9—urine—kidney cancer	0.00106	0.112	CbGeAlD
Cyclophosphamide—CYP3A4—urine—kidney cancer	0.000809	0.0854	CbGeAlD
Cyclophosphamide—CYP2D6—urine—kidney cancer	0.000796	0.0841	CbGeAlD
Cyclophosphamide—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000701	0.074	CbGeAlD
Cyclophosphamide—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.0006	0.0634	CbGeAlD
Cyclophosphamide—CYP2C8—renal system—kidney cancer	0.000292	0.0309	CbGeAlD
Cyclophosphamide—CYP3A5—nephron tubule—kidney cancer	0.00029	0.0306	CbGeAlD
Cyclophosphamide—CYP2B6—nephron tubule—kidney cancer	0.000288	0.0305	CbGeAlD
Cyclophosphamide—CYP2C8—kidney—kidney cancer	0.000283	0.0298	CbGeAlD
Cyclophosphamide—CYP3A5—renal system—kidney cancer	0.000264	0.0279	CbGeAlD
Cyclophosphamide—CYP2B6—renal system—kidney cancer	0.000262	0.0277	CbGeAlD
Cyclophosphamide—CYP3A5—kidney—kidney cancer	0.000255	0.0269	CbGeAlD
Cyclophosphamide—CYP2B6—kidney—kidney cancer	0.000253	0.0268	CbGeAlD
Cyclophosphamide—CYP3A5—cortex of kidney—kidney cancer	0.000248	0.0262	CbGeAlD
Cyclophosphamide—CYP2B6—gonad—kidney cancer	0.000235	0.0248	CbGeAlD
Cyclophosphamide—CYP3A4—renal system—kidney cancer	0.000198	0.0209	CbGeAlD
Cyclophosphamide—CYP2D6—renal system—kidney cancer	0.000195	0.0206	CbGeAlD
Cyclophosphamide—CYP3A4—kidney—kidney cancer	0.000191	0.0202	CbGeAlD
Cyclophosphamide—CYP2D6—kidney—kidney cancer	0.000188	0.0199	CbGeAlD
Cyclophosphamide—ABCB1—nephron tubule—kidney cancer	0.000154	0.0163	CbGeAlD
Cyclophosphamide—ABCB1—renal system—kidney cancer	0.00014	0.0148	CbGeAlD
Cyclophosphamide—ABCB1—kidney—kidney cancer	0.000135	0.0143	CbGeAlD
Cyclophosphamide—ABCB1—cortex of kidney—kidney cancer	0.000132	0.0139	CbGeAlD
Cyclophosphamide—ABCB1—gonad—kidney cancer	0.000126	0.0133	CbGeAlD
Cyclophosphamide—Anorexia—Gemcitabine—kidney cancer	5.33e-05	0.000219	CcSEcCtD
Cyclophosphamide—Vomiting—Vinblastine—kidney cancer	5.32e-05	0.000219	CcSEcCtD
Cyclophosphamide—Dizziness—Erlotinib—kidney cancer	5.32e-05	0.000219	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Paclitaxel—kidney cancer	5.32e-05	0.000219	CcSEcCtD
Cyclophosphamide—Vomiting—Everolimus—kidney cancer	5.3e-05	0.000218	CcSEcCtD
Cyclophosphamide—Anaemia—Paclitaxel—kidney cancer	5.3e-05	0.000218	CcSEcCtD
Cyclophosphamide—Renal impairment—Doxorubicin—kidney cancer	5.29e-05	0.000218	CcSEcCtD
Cyclophosphamide—Paraesthesia—Vincristine—kidney cancer	5.29e-05	0.000218	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Doxorubicin—kidney cancer	5.27e-05	0.000217	CcSEcCtD
Cyclophosphamide—Agitation—Paclitaxel—kidney cancer	5.27e-05	0.000217	CcSEcCtD
Cyclophosphamide—Rash—Everolimus—kidney cancer	5.26e-05	0.000217	CcSEcCtD
Cyclophosphamide—Dermatitis—Everolimus—kidney cancer	5.25e-05	0.000216	CcSEcCtD
Cyclophosphamide—Headache—Vinblastine—kidney cancer	5.25e-05	0.000216	CcSEcCtD
Cyclophosphamide—Headache—Everolimus—kidney cancer	5.22e-05	0.000215	CcSEcCtD
Cyclophosphamide—Hypotension—Gemcitabine—kidney cancer	5.22e-05	0.000215	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dactinomycin—kidney cancer	5.21e-05	0.000215	CcSEcCtD
Cyclophosphamide—Visual impairment—Capecitabine—kidney cancer	5.21e-05	0.000214	CcSEcCtD
Cyclophosphamide—Asthenia—Sorafenib—kidney cancer	5.19e-05	0.000214	CcSEcCtD
Cyclophosphamide—Malaise—Paclitaxel—kidney cancer	5.17e-05	0.000213	CcSEcCtD
Cyclophosphamide—Cardiac failure—Doxorubicin—kidney cancer	5.16e-05	0.000213	CcSEcCtD
Cyclophosphamide—Leukopenia—Paclitaxel—kidney cancer	5.13e-05	0.000211	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Sunitinib—kidney cancer	5.13e-05	0.000211	CcSEcCtD
Cyclophosphamide—Decreased appetite—Vincristine—kidney cancer	5.12e-05	0.000211	CcSEcCtD
Cyclophosphamide—Pruritus—Sorafenib—kidney cancer	5.12e-05	0.000211	CcSEcCtD
Cyclophosphamide—Vomiting—Erlotinib—kidney cancer	5.12e-05	0.000211	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Capecitabine—kidney cancer	5.11e-05	0.00021	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Gemcitabine—kidney cancer	5.09e-05	0.00021	CcSEcCtD
Cyclophosphamide—Fatigue—Vincristine—kidney cancer	5.08e-05	0.000209	CcSEcCtD
Cyclophosphamide—Rash—Erlotinib—kidney cancer	5.07e-05	0.000209	CcSEcCtD
Cyclophosphamide—Dermatitis—Erlotinib—kidney cancer	5.07e-05	0.000209	CcSEcCtD
Cyclophosphamide—Palpitations—Paclitaxel—kidney cancer	5.07e-05	0.000209	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—kidney cancer	5.06e-05	0.000208	CcSEcCtD
Cyclophosphamide—Headache—Erlotinib—kidney cancer	5.04e-05	0.000208	CcSEcCtD
Cyclophosphamide—Tinnitus—Capecitabine—kidney cancer	5.04e-05	0.000208	CcSEcCtD
Cyclophosphamide—Pain—Vincristine—kidney cancer	5.04e-05	0.000207	CcSEcCtD
Cyclophosphamide—Constipation—Vincristine—kidney cancer	5.04e-05	0.000207	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	5.04e-05	0.000207	CcSEcCtD
Cyclophosphamide—Paraesthesia—Gemcitabine—kidney cancer	5.02e-05	0.000207	CcSEcCtD
Cyclophosphamide—Flushing—Capecitabine—kidney cancer	5.02e-05	0.000207	CcSEcCtD
Cyclophosphamide—Cough—Paclitaxel—kidney cancer	5e-05	0.000206	CcSEcCtD
Cyclophosphamide—Asthenia—Sunitinib—kidney cancer	5e-05	0.000206	CcSEcCtD
Cyclophosphamide—Dyspnoea—Gemcitabine—kidney cancer	4.98e-05	0.000205	CcSEcCtD
Cyclophosphamide—Nausea—Vinblastine—kidney cancer	4.97e-05	0.000205	CcSEcCtD
Cyclophosphamide—Convulsion—Paclitaxel—kidney cancer	4.97e-05	0.000205	CcSEcCtD
Cyclophosphamide—Nausea—Everolimus—kidney cancer	4.95e-05	0.000204	CcSEcCtD
Cyclophosphamide—Diarrhoea—Sorafenib—kidney cancer	4.95e-05	0.000204	CcSEcCtD
Cyclophosphamide—Hypertension—Paclitaxel—kidney cancer	4.95e-05	0.000204	CcSEcCtD
Cyclophosphamide—Pruritus—Sunitinib—kidney cancer	4.93e-05	0.000203	CcSEcCtD
Cyclophosphamide—Chest pain—Paclitaxel—kidney cancer	4.88e-05	0.000201	CcSEcCtD
Cyclophosphamide—Arthralgia—Paclitaxel—kidney cancer	4.88e-05	0.000201	CcSEcCtD
Cyclophosphamide—Myalgia—Paclitaxel—kidney cancer	4.88e-05	0.000201	CcSEcCtD
Cyclophosphamide—Decreased appetite—Gemcitabine—kidney cancer	4.86e-05	0.0002	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Dactinomycin—kidney cancer	4.86e-05	0.0002	CcSEcCtD
Cyclophosphamide—Chills—Capecitabine—kidney cancer	4.85e-05	0.0002	CcSEcCtD
Cyclophosphamide—Arrhythmia—Capecitabine—kidney cancer	4.83e-05	0.000199	CcSEcCtD
Cyclophosphamide—Discomfort—Paclitaxel—kidney cancer	4.82e-05	0.000199	CcSEcCtD
Cyclophosphamide—Fatigue—Gemcitabine—kidney cancer	4.82e-05	0.000198	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—kidney cancer	4.79e-05	0.000197	CcSEcCtD
Cyclophosphamide—Dizziness—Sorafenib—kidney cancer	4.79e-05	0.000197	CcSEcCtD
Cyclophosphamide—Constipation—Gemcitabine—kidney cancer	4.78e-05	0.000197	CcSEcCtD
Cyclophosphamide—Pain—Gemcitabine—kidney cancer	4.78e-05	0.000197	CcSEcCtD
Cyclophosphamide—Nausea—Erlotinib—kidney cancer	4.78e-05	0.000197	CcSEcCtD
Cyclophosphamide—Alopecia—Capecitabine—kidney cancer	4.78e-05	0.000197	CcSEcCtD
Cyclophosphamide—Diarrhoea—Sunitinib—kidney cancer	4.77e-05	0.000196	CcSEcCtD
Cyclophosphamide—Asthenia—Dactinomycin—kidney cancer	4.73e-05	0.000195	CcSEcCtD
Cyclophosphamide—Confusional state—Paclitaxel—kidney cancer	4.72e-05	0.000194	CcSEcCtD
Cyclophosphamide—Erythema—Capecitabine—kidney cancer	4.71e-05	0.000194	CcSEcCtD
Cyclophosphamide—Oedema—Paclitaxel—kidney cancer	4.68e-05	0.000193	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Paclitaxel—kidney cancer	4.68e-05	0.000193	CcSEcCtD
Cyclophosphamide—Body temperature increased—Vincristine—kidney cancer	4.66e-05	0.000192	CcSEcCtD
Cyclophosphamide—Infection—Paclitaxel—kidney cancer	4.65e-05	0.000191	CcSEcCtD
Cyclophosphamide—Dysgeusia—Capecitabine—kidney cancer	4.61e-05	0.00019	CcSEcCtD
Cyclophosphamide—Dizziness—Sunitinib—kidney cancer	4.61e-05	0.00019	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Gemcitabine—kidney cancer	4.61e-05	0.00019	CcSEcCtD
Cyclophosphamide—Shock—Paclitaxel—kidney cancer	4.6e-05	0.00019	CcSEcCtD
Cyclophosphamide—Vomiting—Sorafenib—kidney cancer	4.6e-05	0.00019	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Paclitaxel—kidney cancer	4.58e-05	0.000189	CcSEcCtD
Cyclophosphamide—Tachycardia—Paclitaxel—kidney cancer	4.57e-05	0.000188	CcSEcCtD
Cyclophosphamide—Rash—Sorafenib—kidney cancer	4.56e-05	0.000188	CcSEcCtD
Cyclophosphamide—Dermatitis—Sorafenib—kidney cancer	4.56e-05	0.000188	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.54e-05	0.000187	CcSEcCtD
Cyclophosphamide—Headache—Sorafenib—kidney cancer	4.54e-05	0.000187	CcSEcCtD
Cyclophosphamide—Muscle spasms—Capecitabine—kidney cancer	4.52e-05	0.000186	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Paclitaxel—kidney cancer	4.52e-05	0.000186	CcSEcCtD
Cyclophosphamide—Diarrhoea—Dactinomycin—kidney cancer	4.51e-05	0.000186	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—kidney cancer	4.5e-05	0.000185	CcSEcCtD
Cyclophosphamide—Anorexia—Paclitaxel—kidney cancer	4.46e-05	0.000184	CcSEcCtD
Cyclophosphamide—Vision blurred—Capecitabine—kidney cancer	4.43e-05	0.000183	CcSEcCtD
Cyclophosphamide—Vomiting—Sunitinib—kidney cancer	4.43e-05	0.000182	CcSEcCtD
Cyclophosphamide—Body temperature increased—Gemcitabine—kidney cancer	4.42e-05	0.000182	CcSEcCtD
Cyclophosphamide—Tremor—Capecitabine—kidney cancer	4.41e-05	0.000182	CcSEcCtD
Cyclophosphamide—Rash—Sunitinib—kidney cancer	4.39e-05	0.000181	CcSEcCtD
Cyclophosphamide—Dermatitis—Sunitinib—kidney cancer	4.39e-05	0.000181	CcSEcCtD
Cyclophosphamide—Hypotension—Paclitaxel—kidney cancer	4.37e-05	0.00018	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Capecitabine—kidney cancer	4.37e-05	0.00018	CcSEcCtD
Cyclophosphamide—Headache—Sunitinib—kidney cancer	4.36e-05	0.00018	CcSEcCtD
Cyclophosphamide—Anaemia—Capecitabine—kidney cancer	4.35e-05	0.000179	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Vincristine—kidney cancer	4.34e-05	0.000179	CcSEcCtD
Cyclophosphamide—Nausea—Sorafenib—kidney cancer	4.3e-05	0.000177	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	4.26e-05	0.000176	CcSEcCtD
Cyclophosphamide—Malaise—Capecitabine—kidney cancer	4.24e-05	0.000175	CcSEcCtD
Cyclophosphamide—Asthenia—Vincristine—kidney cancer	4.23e-05	0.000174	CcSEcCtD
Cyclophosphamide—Leukopenia—Capecitabine—kidney cancer	4.21e-05	0.000173	CcSEcCtD
Cyclophosphamide—Paraesthesia—Paclitaxel—kidney cancer	4.2e-05	0.000173	CcSEcCtD
Cyclophosphamide—Vomiting—Dactinomycin—kidney cancer	4.19e-05	0.000173	CcSEcCtD
Cyclophosphamide—Dyspnoea—Paclitaxel—kidney cancer	4.17e-05	0.000172	CcSEcCtD
Cyclophosphamide—Palpitations—Capecitabine—kidney cancer	4.16e-05	0.000171	CcSEcCtD
Cyclophosphamide—Rash—Dactinomycin—kidney cancer	4.16e-05	0.000171	CcSEcCtD
Cyclophosphamide—Nausea—Sunitinib—kidney cancer	4.14e-05	0.00017	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—kidney cancer	4.13e-05	0.00017	CcSEcCtD
Cyclophosphamide—Cough—Capecitabine—kidney cancer	4.11e-05	0.000169	CcSEcCtD
Cyclophosphamide—Decreased appetite—Paclitaxel—kidney cancer	4.07e-05	0.000168	CcSEcCtD
Cyclophosphamide—Hypertension—Capecitabine—kidney cancer	4.06e-05	0.000167	CcSEcCtD
Cyclophosphamide—Fatigue—Paclitaxel—kidney cancer	4.03e-05	0.000166	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vincristine—kidney cancer	4.03e-05	0.000166	CcSEcCtD
Cyclophosphamide—Asthenia—Gemcitabine—kidney cancer	4.01e-05	0.000165	CcSEcCtD
Cyclophosphamide—Arthralgia—Capecitabine—kidney cancer	4.01e-05	0.000165	CcSEcCtD
Cyclophosphamide—Myalgia—Capecitabine—kidney cancer	4.01e-05	0.000165	CcSEcCtD
Cyclophosphamide—Chest pain—Capecitabine—kidney cancer	4.01e-05	0.000165	CcSEcCtD
Cyclophosphamide—Constipation—Paclitaxel—kidney cancer	4e-05	0.000165	CcSEcCtD
Cyclophosphamide—Pain—Paclitaxel—kidney cancer	4e-05	0.000165	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—kidney cancer	3.96e-05	0.000163	CcSEcCtD
Cyclophosphamide—Discomfort—Capecitabine—kidney cancer	3.96e-05	0.000163	CcSEcCtD
Cyclophosphamide—Pruritus—Gemcitabine—kidney cancer	3.95e-05	0.000163	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—kidney cancer	3.93e-05	0.000162	CcSEcCtD
Cyclophosphamide—Nausea—Dactinomycin—kidney cancer	3.92e-05	0.000161	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—kidney cancer	3.9e-05	0.000161	CcSEcCtD
Cyclophosphamide—Dizziness—Vincristine—kidney cancer	3.9e-05	0.00016	CcSEcCtD
Cyclophosphamide—Confusional state—Capecitabine—kidney cancer	3.87e-05	0.000159	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Paclitaxel—kidney cancer	3.86e-05	0.000159	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	3.85e-05	0.000158	CcSEcCtD
Cyclophosphamide—Oedema—Capecitabine—kidney cancer	3.84e-05	0.000158	CcSEcCtD
Cyclophosphamide—Diarrhoea—Gemcitabine—kidney cancer	3.82e-05	0.000157	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—kidney cancer	3.82e-05	0.000157	CcSEcCtD
Cyclophosphamide—Infection—Capecitabine—kidney cancer	3.82e-05	0.000157	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—kidney cancer	3.8e-05	0.000157	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—kidney cancer	3.78e-05	0.000156	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—kidney cancer	3.78e-05	0.000156	CcSEcCtD
Cyclophosphamide—Shock—Capecitabine—kidney cancer	3.78e-05	0.000156	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—kidney cancer	3.77e-05	0.000155	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Capecitabine—kidney cancer	3.76e-05	0.000155	CcSEcCtD
Cyclophosphamide—Tachycardia—Capecitabine—kidney cancer	3.75e-05	0.000154	CcSEcCtD
Cyclophosphamide—Vomiting—Vincristine—kidney cancer	3.75e-05	0.000154	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—kidney cancer	3.72e-05	0.000153	CcSEcCtD
Cyclophosphamide—Urticaria—Paclitaxel—kidney cancer	3.72e-05	0.000153	CcSEcCtD
Cyclophosphamide—Rash—Vincristine—kidney cancer	3.72e-05	0.000153	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Capecitabine—kidney cancer	3.71e-05	0.000153	CcSEcCtD
Cyclophosphamide—Dermatitis—Vincristine—kidney cancer	3.71e-05	0.000153	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—kidney cancer	3.7e-05	0.000152	CcSEcCtD
Cyclophosphamide—Body temperature increased—Paclitaxel—kidney cancer	3.7e-05	0.000152	CcSEcCtD
Cyclophosphamide—Headache—Vincristine—kidney cancer	3.69e-05	0.000152	CcSEcCtD
Cyclophosphamide—Anorexia—Capecitabine—kidney cancer	3.66e-05	0.000151	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—kidney cancer	3.62e-05	0.000149	CcSEcCtD
Cyclophosphamide—Hypotension—Capecitabine—kidney cancer	3.59e-05	0.000148	CcSEcCtD
Cyclophosphamide—Vomiting—Gemcitabine—kidney cancer	3.55e-05	0.000146	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—kidney cancer	3.55e-05	0.000146	CcSEcCtD
Cyclophosphamide—Rash—Gemcitabine—kidney cancer	3.52e-05	0.000145	CcSEcCtD
Cyclophosphamide—Dermatitis—Gemcitabine—kidney cancer	3.52e-05	0.000145	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—kidney cancer	3.5e-05	0.000144	CcSEcCtD
Cyclophosphamide—Headache—Gemcitabine—kidney cancer	3.5e-05	0.000144	CcSEcCtD
Cyclophosphamide—Nausea—Vincristine—kidney cancer	3.5e-05	0.000144	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.5e-05	0.000144	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—kidney cancer	3.49e-05	0.000144	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—kidney cancer	3.48e-05	0.000143	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—kidney cancer	3.48e-05	0.000143	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—kidney cancer	3.47e-05	0.000143	CcSEcCtD
Cyclophosphamide—Paraesthesia—Capecitabine—kidney cancer	3.45e-05	0.000142	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Paclitaxel—kidney cancer	3.45e-05	0.000142	CcSEcCtD
Cyclophosphamide—Dyspnoea—Capecitabine—kidney cancer	3.42e-05	0.000141	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—kidney cancer	3.36e-05	0.000138	CcSEcCtD
Cyclophosphamide—Asthenia—Paclitaxel—kidney cancer	3.36e-05	0.000138	CcSEcCtD
Cyclophosphamide—Decreased appetite—Capecitabine—kidney cancer	3.34e-05	0.000137	CcSEcCtD
Cyclophosphamide—Nausea—Gemcitabine—kidney cancer	3.32e-05	0.000137	CcSEcCtD
Cyclophosphamide—Fatigue—Capecitabine—kidney cancer	3.31e-05	0.000136	CcSEcCtD
Cyclophosphamide—Pruritus—Paclitaxel—kidney cancer	3.31e-05	0.000136	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—kidney cancer	3.29e-05	0.000136	CcSEcCtD
Cyclophosphamide—Constipation—Capecitabine—kidney cancer	3.28e-05	0.000135	CcSEcCtD
Cyclophosphamide—Pain—Capecitabine—kidney cancer	3.28e-05	0.000135	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—kidney cancer	3.25e-05	0.000134	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—kidney cancer	3.23e-05	0.000133	CcSEcCtD
Cyclophosphamide—Diarrhoea—Paclitaxel—kidney cancer	3.2e-05	0.000132	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Capecitabine—kidney cancer	3.16e-05	0.00013	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—kidney cancer	3.13e-05	0.000129	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—kidney cancer	3.11e-05	0.000128	CcSEcCtD
Cyclophosphamide—Dizziness—Paclitaxel—kidney cancer	3.09e-05	0.000127	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—kidney cancer	3.08e-05	0.000127	CcSEcCtD
Cyclophosphamide—Urticaria—Capecitabine—kidney cancer	3.05e-05	0.000126	CcSEcCtD
Cyclophosphamide—Body temperature increased—Capecitabine—kidney cancer	3.04e-05	0.000125	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—kidney cancer	3.03e-05	0.000125	CcSEcCtD
Cyclophosphamide—Vomiting—Paclitaxel—kidney cancer	2.98e-05	0.000123	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—kidney cancer	2.97e-05	0.000122	CcSEcCtD
Cyclophosphamide—Rash—Paclitaxel—kidney cancer	2.95e-05	0.000121	CcSEcCtD
Cyclophosphamide—Dermatitis—Paclitaxel—kidney cancer	2.95e-05	0.000121	CcSEcCtD
Cyclophosphamide—Headache—Paclitaxel—kidney cancer	2.93e-05	0.000121	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—kidney cancer	2.92e-05	0.00012	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—kidney cancer	2.86e-05	0.000118	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Capecitabine—kidney cancer	2.83e-05	0.000117	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—kidney cancer	2.81e-05	0.000116	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—kidney cancer	2.8e-05	0.000115	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—kidney cancer	2.79e-05	0.000115	CcSEcCtD
Cyclophosphamide—Nausea—Paclitaxel—kidney cancer	2.78e-05	0.000114	CcSEcCtD
Cyclophosphamide—Asthenia—Capecitabine—kidney cancer	2.76e-05	0.000113	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—kidney cancer	2.74e-05	0.000113	CcSEcCtD
Cyclophosphamide—Pruritus—Capecitabine—kidney cancer	2.72e-05	0.000112	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—kidney cancer	2.72e-05	0.000112	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—kidney cancer	2.68e-05	0.00011	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—kidney cancer	2.65e-05	0.000109	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—kidney cancer	2.63e-05	0.000108	CcSEcCtD
Cyclophosphamide—Diarrhoea—Capecitabine—kidney cancer	2.63e-05	0.000108	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—kidney cancer	2.62e-05	0.000108	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—kidney cancer	2.58e-05	0.000106	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—kidney cancer	2.58e-05	0.000106	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—kidney cancer	2.58e-05	0.000106	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—kidney cancer	2.55e-05	0.000105	CcSEcCtD
Cyclophosphamide—Dizziness—Capecitabine—kidney cancer	2.54e-05	0.000105	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—kidney cancer	2.5e-05	0.000103	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—kidney cancer	2.48e-05	0.000102	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—kidney cancer	2.48e-05	0.000102	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—kidney cancer	2.46e-05	0.000101	CcSEcCtD
Cyclophosphamide—Vomiting—Capecitabine—kidney cancer	2.44e-05	0.000101	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—kidney cancer	2.44e-05	0.0001	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—kidney cancer	2.42e-05	9.98e-05	CcSEcCtD
Cyclophosphamide—Rash—Capecitabine—kidney cancer	2.42e-05	9.97e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Capecitabine—kidney cancer	2.42e-05	9.96e-05	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—kidney cancer	2.42e-05	9.95e-05	CcSEcCtD
Cyclophosphamide—Headache—Capecitabine—kidney cancer	2.41e-05	9.91e-05	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—kidney cancer	2.39e-05	9.85e-05	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—kidney cancer	2.36e-05	9.72e-05	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—kidney cancer	2.31e-05	9.52e-05	CcSEcCtD
Cyclophosphamide—Nausea—Capecitabine—kidney cancer	2.28e-05	9.39e-05	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.26e-05	9.29e-05	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—kidney cancer	2.22e-05	9.15e-05	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—kidney cancer	2.21e-05	9.09e-05	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—kidney cancer	2.15e-05	8.86e-05	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—kidney cancer	2.13e-05	8.79e-05	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—kidney cancer	2.12e-05	8.72e-05	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—kidney cancer	2.12e-05	8.72e-05	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—kidney cancer	2.04e-05	8.4e-05	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—kidney cancer	1.97e-05	8.1e-05	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—kidney cancer	1.96e-05	8.06e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—kidney cancer	1.82e-05	7.51e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—kidney cancer	1.78e-05	7.31e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—kidney cancer	1.75e-05	7.21e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—kidney cancer	1.69e-05	6.97e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—kidney cancer	1.64e-05	6.74e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—kidney cancer	1.57e-05	6.48e-05	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—kidney cancer	1.56e-05	6.43e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—kidney cancer	1.56e-05	6.42e-05	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—kidney cancer	1.55e-05	6.39e-05	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—kidney cancer	1.47e-05	6.05e-05	CcSEcCtD
Cyclophosphamide—CYP2C18—Metabolism—GSTM1—kidney cancer	1.06e-05	0.000347	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.06e-05	0.000345	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ALDH1A1—kidney cancer	1.06e-05	0.000344	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ST3GAL2—kidney cancer	1.06e-05	0.000344	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.06e-05	0.000344	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—SCARB1—kidney cancer	1.05e-05	0.000343	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.05e-05	0.000341	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CA2—kidney cancer	1.05e-05	0.000341	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PTGS1—kidney cancer	1.04e-05	0.000339	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CA2—kidney cancer	1.04e-05	0.000338	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ALDH1A1—kidney cancer	1.03e-05	0.000336	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PSMD7—kidney cancer	1.02e-05	0.000333	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.02e-05	0.000333	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ALAD—kidney cancer	1.02e-05	0.000332	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTT1—kidney cancer	1.02e-05	0.000332	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—ACHE—kidney cancer	1.02e-05	0.000332	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PGK1—kidney cancer	1.01e-05	0.00033	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—SLC5A3—kidney cancer	1.01e-05	0.00033	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ALAD—kidney cancer	1.01e-05	0.000329	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CYP1A1—kidney cancer	1.01e-05	0.000329	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ST3GAL2—kidney cancer	9.95e-06	0.000324	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—LDHB—kidney cancer	9.94e-06	0.000324	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PGK1—kidney cancer	9.89e-06	0.000322	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—SLC5A3—kidney cancer	9.89e-06	0.000322	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PDHB—kidney cancer	9.86e-06	0.000321	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ST3GAL2—kidney cancer	9.86e-06	0.000321	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Biological oxidations—POMC—kidney cancer	9.83e-06	0.00032	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ALDH1A1—kidney cancer	9.72e-06	0.000317	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—LDHB—kidney cancer	9.7e-06	0.000316	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CRABP1—kidney cancer	9.69e-06	0.000316	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—BCHE—kidney cancer	9.68e-06	0.000315	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CA9—kidney cancer	9.65e-06	0.000314	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—SCARB1—kidney cancer	9.64e-06	0.000314	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ALDH1A1—kidney cancer	9.64e-06	0.000314	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—SLC5A5—kidney cancer	9.56e-06	0.000312	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PTGS1—kidney cancer	9.55e-06	0.000311	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CRABP1—kidney cancer	9.48e-06	0.000309	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	9.43e-06	0.000307	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PSMD7—kidney cancer	9.36e-06	0.000305	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PGK1—kidney cancer	9.32e-06	0.000304	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—SLC5A3—kidney cancer	9.32e-06	0.000304	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CCBL1—kidney cancer	9.27e-06	0.000302	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PGK1—kidney cancer	9.24e-06	0.000301	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—SLC5A3—kidney cancer	9.24e-06	0.000301	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—SLC2A1—kidney cancer	9.24e-06	0.000301	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	9.22e-06	0.0003	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—LDHB—kidney cancer	9.14e-06	0.000298	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—LDHB—kidney cancer	9.06e-06	0.000295	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ITPR2—kidney cancer	9.01e-06	0.000294	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—BCHE—kidney cancer	8.87e-06	0.000289	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ITPR2—kidney cancer	8.81e-06	0.000287	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—SLC5A5—kidney cancer	8.77e-06	0.000286	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	8.72e-06	0.000284	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CA9—kidney cancer	8.62e-06	0.000281	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	8.48e-06	0.000276	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—SLC2A1—kidney cancer	8.47e-06	0.000276	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	8.42e-06	0.000274	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CA9—kidney cancer	8.41e-06	0.000274	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	8.3e-06	0.00027	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTT1—kidney cancer	8.22e-06	0.000268	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ACHE—kidney cancer	8.22e-06	0.000268	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CRABP1—kidney cancer	8.21e-06	0.000267	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PPAT—kidney cancer	8.04e-06	0.000262	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GLIPR1—kidney cancer	8.04e-06	0.000262	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ACHE—kidney cancer	8.03e-06	0.000262	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTT1—kidney cancer	8.03e-06	0.000262	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CA9—kidney cancer	7.92e-06	0.000258	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CA9—kidney cancer	7.86e-06	0.000256	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	7.84e-06	0.000255	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—SCARB1—kidney cancer	7.78e-06	0.000253	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GSTP1—kidney cancer	7.7e-06	0.000251	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PTGS1—kidney cancer	7.7e-06	0.000251	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	7.68e-06	0.00025	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ITPR2—kidney cancer	7.63e-06	0.000249	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—SCARB1—kidney cancer	7.6e-06	0.000248	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PSMD7—kidney cancer	7.55e-06	0.000246	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PTGS1—kidney cancer	7.53e-06	0.000245	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—POMC—kidney cancer	7.53e-06	0.000245	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—APRT—kidney cancer	7.47e-06	0.000243	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—FH—kidney cancer	7.47e-06	0.000243	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PSMD7—kidney cancer	7.38e-06	0.00024	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CRABP1—kidney cancer	7.33e-06	0.000239	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—ABCB1—kidney cancer	7.29e-06	0.000238	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	7.2e-06	0.000235	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—BCHE—kidney cancer	7.16e-06	0.000233	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CRABP1—kidney cancer	7.15e-06	0.000233	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GSTM1—kidney cancer	7.08e-06	0.000231	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—SLC5A5—kidney cancer	7.07e-06	0.00023	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTP1—kidney cancer	7.06e-06	0.00023	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.03e-06	0.000229	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GPC3—kidney cancer	7.03e-06	0.000229	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—BCHE—kidney cancer	7e-06	0.000228	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	6.97e-06	0.000227	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTT1—kidney cancer	6.96e-06	0.000227	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ACHE—kidney cancer	6.96e-06	0.000227	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—SLC5A5—kidney cancer	6.91e-06	0.000225	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CA2—kidney cancer	6.84e-06	0.000223	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—SLC2A1—kidney cancer	6.83e-06	0.000223	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ITPR2—kidney cancer	6.81e-06	0.000222	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CRABP1—kidney cancer	6.74e-06	0.000219	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CYP1A1—kidney cancer	6.71e-06	0.000219	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—ABCB1—kidney cancer	6.68e-06	0.000218	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CRABP1—kidney cancer	6.68e-06	0.000218	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—SLC2A1—kidney cancer	6.68e-06	0.000217	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ALAD—kidney cancer	6.66e-06	0.000217	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ITPR2—kidney cancer	6.65e-06	0.000217	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—SCARB1—kidney cancer	6.59e-06	0.000215	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PTGS1—kidney cancer	6.52e-06	0.000212	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ST3GAL2—kidney cancer	6.5e-06	0.000212	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTM1—kidney cancer	6.49e-06	0.000211	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PSMD7—kidney cancer	6.39e-06	0.000208	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.36e-06	0.000207	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.28e-06	0.000205	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ITPR2—kidney cancer	6.26e-06	0.000204	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ACHE—kidney cancer	6.21e-06	0.000202	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTT1—kidney cancer	6.21e-06	0.000202	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ITPR2—kidney cancer	6.21e-06	0.000202	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CYP1A1—kidney cancer	6.15e-06	0.0002	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SLC5A3—kidney cancer	6.09e-06	0.000198	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PGK1—kidney cancer	6.09e-06	0.000198	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ACHE—kidney cancer	6.06e-06	0.000197	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTT1—kidney cancer	6.06e-06	0.000197	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—BCHE—kidney cancer	6.06e-06	0.000197	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PTGS2—kidney cancer	6e-06	0.000196	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—SLC5A5—kidney cancer	5.99e-06	0.000195	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—LDHB—kidney cancer	5.98e-06	0.000195	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—SCARB1—kidney cancer	5.88e-06	0.000192	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PTGS1—kidney cancer	5.82e-06	0.00019	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—SLC2A1—kidney cancer	5.78e-06	0.000188	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—SCARB1—kidney cancer	5.74e-06	0.000187	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.72e-06	0.000186	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ACHE—kidney cancer	5.71e-06	0.000186	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTT1—kidney cancer	5.71e-06	0.000186	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PSMD7—kidney cancer	5.71e-06	0.000186	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTP1—kidney cancer	5.7e-06	0.000186	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PTGS1—kidney cancer	5.68e-06	0.000185	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTT1—kidney cancer	5.66e-06	0.000184	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ACHE—kidney cancer	5.66e-06	0.000184	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.61e-06	0.000183	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PSMD7—kidney cancer	5.57e-06	0.000181	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTP1—kidney cancer	5.57e-06	0.000181	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—BCHE—kidney cancer	5.41e-06	0.000176	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—SCARB1—kidney cancer	5.41e-06	0.000176	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ABCB1—kidney cancer	5.39e-06	0.000176	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—SCARB1—kidney cancer	5.36e-06	0.000175	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PTGS1—kidney cancer	5.35e-06	0.000174	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—SLC5A5—kidney cancer	5.34e-06	0.000174	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PTGS1—kidney cancer	5.31e-06	0.000173	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—BCHE—kidney cancer	5.28e-06	0.000172	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ABCB1—kidney cancer	5.27e-06	0.000172	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PSMD7—kidney cancer	5.25e-06	0.000171	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTM1—kidney cancer	5.24e-06	0.000171	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PTEN—kidney cancer	5.24e-06	0.000171	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—SLC5A5—kidney cancer	5.22e-06	0.00017	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PSMD7—kidney cancer	5.2e-06	0.00017	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CA9—kidney cancer	5.18e-06	0.000169	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—SLC2A1—kidney cancer	5.16e-06	0.000168	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTM1—kidney cancer	5.12e-06	0.000167	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—SLC2A1—kidney cancer	5.04e-06	0.000164	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.01e-06	0.000163	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—POMC—kidney cancer	5e-06	0.000163	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—BCHE—kidney cancer	4.98e-06	0.000162	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYP1A1—kidney cancer	4.96e-06	0.000162	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—BCHE—kidney cancer	4.93e-06	0.000161	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—SLC5A5—kidney cancer	4.92e-06	0.00016	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.89e-06	0.000159	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—SLC5A5—kidney cancer	4.87e-06	0.000159	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP1A1—kidney cancer	4.85e-06	0.000158	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTP1—kidney cancer	4.82e-06	0.000157	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.8e-06	0.000157	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—SLC2A1—kidney cancer	4.75e-06	0.000155	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—SLC2A1—kidney cancer	4.71e-06	0.000153	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—POMC—kidney cancer	4.59e-06	0.000149	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.57e-06	0.000149	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ABCB1—kidney cancer	4.57e-06	0.000149	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTM1—kidney cancer	4.43e-06	0.000144	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CRABP1—kidney cancer	4.41e-06	0.000144	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.37e-06	0.000142	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTP1—kidney cancer	4.31e-06	0.00014	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTP1—kidney cancer	4.2e-06	0.000137	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYP1A1—kidney cancer	4.2e-06	0.000137	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ITPR2—kidney cancer	4.1e-06	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ABCB1—kidney cancer	4.08e-06	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PTGS2—kidney cancer	3.99e-06	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.98e-06	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTP1—kidney cancer	3.96e-06	0.000129	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTM1—kidney cancer	3.96e-06	0.000129	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTP1—kidney cancer	3.93e-06	0.000128	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTM1—kidney cancer	3.86e-06	0.000126	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYP1A1—kidney cancer	3.75e-06	0.000122	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ABCB1—kidney cancer	3.75e-06	0.000122	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ACHE—kidney cancer	3.73e-06	0.000122	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTT1—kidney cancer	3.73e-06	0.000122	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ABCB1—kidney cancer	3.72e-06	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—POMC—kidney cancer	3.7e-06	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PIK3CA—kidney cancer	3.69e-06	0.00012	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP1A1—kidney cancer	3.66e-06	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PTGS2—kidney cancer	3.66e-06	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTM1—kidney cancer	3.64e-06	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—POMC—kidney cancer	3.62e-06	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTM1—kidney cancer	3.61e-06	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SCARB1—kidney cancer	3.54e-06	0.000115	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PTGS1—kidney cancer	3.5e-06	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PTEN—kidney cancer	3.48e-06	0.000113	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.45e-06	0.000112	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.45e-06	0.000112	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PSMD7—kidney cancer	3.43e-06	0.000112	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.42e-06	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—BCHE—kidney cancer	3.25e-06	0.000106	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.21e-06	0.000105	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PTEN—kidney cancer	3.19e-06	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—POMC—kidney cancer	3.13e-06	0.000102	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.1e-06	0.000101	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.08e-06	0.0001	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PTGS2—kidney cancer	2.95e-06	9.61e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PTGS2—kidney cancer	2.88e-06	9.4e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.81e-06	9.15e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—POMC—kidney cancer	2.8e-06	9.11e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—POMC—kidney cancer	2.73e-06	8.89e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTP1—kidney cancer	2.59e-06	8.43e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PTEN—kidney cancer	2.57e-06	8.38e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—POMC—kidney cancer	2.57e-06	8.38e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—POMC—kidney cancer	2.55e-06	8.31e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PTEN—kidney cancer	2.52e-06	8.2e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PTGS2—kidney cancer	2.5e-06	8.14e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CA—kidney cancer	2.46e-06	8e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ABCB1—kidney cancer	2.45e-06	7.98e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTM1—kidney cancer	2.38e-06	7.75e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.26e-06	7.35e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CA—kidney cancer	2.25e-06	7.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PTGS2—kidney cancer	2.23e-06	7.27e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PTEN—kidney cancer	2.18e-06	7.1e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PTGS2—kidney cancer	2.18e-06	7.09e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PTGS2—kidney cancer	2.05e-06	6.68e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PTGS2—kidney cancer	2.03e-06	6.62e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PTEN—kidney cancer	1.95e-06	6.34e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PTEN—kidney cancer	1.9e-06	6.18e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CA—kidney cancer	1.82e-06	5.92e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PTEN—kidney cancer	1.79e-06	5.83e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.77e-06	5.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PTEN—kidney cancer	1.77e-06	5.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—POMC—kidney cancer	1.68e-06	5.48e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.54e-06	5.01e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.37e-06	4.47e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PTGS2—kidney cancer	1.34e-06	4.37e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CA—kidney cancer	1.34e-06	4.36e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.26e-06	4.11e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.25e-06	4.08e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PTEN—kidney cancer	1.17e-06	3.81e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.25e-07	2.69e-05	CbGpPWpGaD
